Benjamin Scot Bergo

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

RPS Diagnostics, Inc. develops diagnostic solutions and medical instruments. Its product FebriDx is in-office test that uses a finger stick blood sample to help differentiate viral from bacterial acute respiratory infection. The company was founded by Robert P. Sambursky in 2004 and is headquartered in Sarasota, FL.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.